METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE

• US 20110280909A1
• Filed: 01/29/2010
• Published: 11/17/2011
• Est. Priority Date: 01/29/2009
• Status: Abandoned Application

• Current Assignee: Kambiz Thomas Moazed
• Original Assignee: Kambiz Thomas Moazed
• Inventors: Moazed, Kambiz Thomas
• Application Number:
  US13/138,260
• Publication Number:
  US 20110280909A1
• Time in Patent Office: Days
• US Class Current: 424/239.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/14 Quaternary ammonium compounds, e.g. edrophonium, choline betaines A61K31/205
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/201 having one or two double bonds, e.g. oleic, linoleic acids
• CPC Class Codes: A61K 31/222 with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• CPC Class Codes: A61K 31/231 having one or two double bonds
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/472 Non-condensed isoquinolines, e.g. papaverine
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/541 Non-condensed thiazines containing further heterocyclic rings
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 27/06 : Antiglaucoma agents or miotics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents

Abstract

Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.

Claims

1. A method of lightening the color of the iris of a human subject, the method comprising administering to the iris of the human subject an amount of a composition comprising a tyrosinase inhibitor effective to lighten the color of the iris of the human subject.

2. The method of claim 1, wherein the tyrosinase inhibitor is hydroquinone,

3. The method of claim 1, wherein in the tyrosinase inhibitor is oxyresveratrol or tetrahydroxyisoflavone.

4. The method of any one of claims 1-3, wherein the composition further comprises at least one melanogenesis inhibitor.

5. The method of claim 4, wherein the melanogenesis inhibitor is selected from the group consisting of glutamate receptor blocker, an α

-adrenergic blocker, a matrix metalloproteinases inhibitor, a Cox inhibitor, a cholinergic agonist, a downregulator of mitf, tyr &

Trp1, an acidifier of melanosomes, an opioid receptor antagonist, a Pmel17 blocker, and a fibroblast growth factor inhibitor.

6. The method of claim 5, wherein the glutamate receptor blocker is memantine, the α

-adrenergic blocker is thymoxamine, the matrix metalloproteinases inhibitor is prinomastat, the Cox inhibitor is bromfenac, the cholinergic agonist is pilocarpine, the downregulator of mitf, tyr &

Trp1 is Haginin A or 4,4′

-dihyldroxybiphenyl, the acidifier of melanosomes is H89, the opioid receptor antagonist is naloxone, and the Pmel17 blocker is calmodulin inhibitors.

7. The method of any one of claims 4-6, wherein the composition comprises hydroquinone, memantine and Haginin A.

8. The method of any one of claims 4-6, wherein the composition comprises oxyresveratrol, 4,4′

-dihyldroxybiphenyl and H89.

9. The method of any one of claims 4-6, wherein the composition comprises tetrahydroxyisoflavone, prinomastat and naloxone.

10. The method of any one of claims 1-9, wherein the composition is administered in conjunction with an injection of saline, siRNA, botulinum toxin, or a combination of botulinum toxin and siRNA.

11. The method of any one of claims 1-10, wherein the composition is administered through a nanoparticle drug delivery system containing a targeting agent of iridial melanocytes.

12. The method of claim 11, wherein the targeting agent is a composition of zinc.

13. The method of claim 12, wherein the composition of zinc is zinc oxide.

14. The method of any one of claims 1-13, wherein the composition is in the form of eye drops.

15. The method of any one of claims 1-13, wherein the composition is administered through an ophthalmic drug delivery system selecting from the group consisting of salves, creams, emulsions and gels.

16. The method of claim 14 or 15, wherein the composition is administered in the fornices under the eyelid.

17. The method of any one of claims 1-13, wherein the composition is administered through an ophthalmic drug delivery system comprising a time-release coated insert.

18. The method of claim 17, wherein the time-release coated insert is coated on at least one side.

19. The method of any one of claims 1-18, wherein the subject is a healthy human.

20. The method of any one of claims 1-18, wherein the subject is afflicted with glaucoma.

44. A method of depigmenting the iris melanocytes to lighten the color of the iris, comprising the steps of:

Blocking the sympathetic and parasympathetic nerve supply to the melanocytes using botulinum toxin and memantine;

Preventing tyrosine conversion to melanin by one of available tyrosinase inhibitors;

Preventing Melanocyte-stimulating hormone activation (MSH) by using 2,5-Dimethyl-4-hydroxy-3(2H)-furanone (DMHF);

Inhibiting the COX-2 enzyme using NSAIDS;

Preventing melanogenesis by using a cholinergic agonist;

Blocking Alpha 1-adrenergic receptors by using antagonist chemicals, or a combination thereof, and

using the subject matter of any one of the preceding claims for delivering depigmenting compositions to melanocytes in the iris.

21. A method of introducing pigments to the iris of a human subject, comprising administering to the iris an amount of at least one melanogenesis promoter, effective to introduce pigments to the iris of the human subject.

22. The method of claim 21, wherein the iris of the human subject darkens after the introduction of pigments to the iris.

23. The method of claim 22, wherein the at least one melanogenesis promoter is prostaglandin, forskolin, 1-oleoyl-2-acetylglycerol and 1,2-diacylglycerol, or lotus flower essential oil, or a combination thereof.

28. The method of any one of claims 21-27, wherein the composition is administered through a nanoparticle drug delivery system containing a targeting agent of iridial melanocytes.

29. The method of claim 28, wherein the targeting agent is a composition of zinc.

30. The method of claims 29, wherein the composition of zinc is zinc oxide.

24. A method of introducing pigments to the iris of a human subject, comprising administering to the iris an amount of a composition comprising a biological dye, effective to introduce pigment to the iris of the human subject.

25. The method of claim 24, wherein the biological dye is a Trypan Blue or a Methyl Green biological dye.

26. The method of claim 24 or 25, wherein the composition further comprises fluorescein.

27. The method of claim 26, wherein the iris of the human subject changes color and/or glows.

31. A nanoparticle composition for lightening pigmented tissues, comprising a targeting agent of melanocytes chemically bound to a pharmaceutical composition comprising a tyrosinase inhibitor.

32. The nanoparticle composition of claim 31, wherein the targeting agent is a composition of zinc.

33. The nanoparticle composition of claim 32, wherein the composition of zinc is zinc oxide.

34. The nanoparticle composition of any one of claims 31-33, wherein the tyrosinase inhibitor is hydroquinone.

35. The nanoparticle composition of any one of claims 31-34, wherein the pharmaceutical composition further comprises at least one melanogenesis inhibitor.

36. The nanoparticle composition of any one of claims 31-35, wherein the pigmented tissues are skin or hair tissues.

37. The nanoparticle composition of any one of claims 31-36, which is in the form of an injectable solution or a topically applied solution.

38. A method for lightening pigmented tissues of a human subject, comprising administering the nanoparticle composition of any one of claims 31-37 to the human subject so as to lighten the pigmented tissues, wherein the targeting agent binds to cells of the pigmented tissues to permit the release of the pharmaceutical composition directly into the cells of the pigmented tissues without affecting non-pigmented cells.

42. The nanoparticle composition of any one of claims 38-40, wherein the disease is glaucoma or melanoma cancer.

43. A method for treating a pigmented tissue related disease, comprising administering the nanoparticle composition of any one of claims 38-42 to the subject so as to treat the disease, wherein the targeting agent binds to cells of the diseased pigmented tissue to permit the release of the pharmaceutical composition directly into the cells of the diseased pigmented tissue without affecting non-pigmented cells.

39. A nanoparticle composition for treating a pigmented tissue related disease, comprising a targeting agent of melanocytes chemically bound to a pharmaceutical composition comprising an active agent for the disease.

40. The nanoparticle composition of claim 39, wherein the targeting agent is a zinc composition.

41. The nanoparticle composition of claim 40, wherein the zinc composition is zinc oxide.